HRSA Launches 340B Rebate Model Pilot Program

If you work with the 340B Drug Pricing Program, you’ve probably noticed that the phrase
“status quo” has quietly left the chat. In 2025, the Health Resources and Services
Administration (HRSA) unveiled the 340B Rebate Model Pilot Programa major
shift that replaces the familiar upfront 340B drug discount with after-the-fact rebates on a
small but very consequential group of high-cost drugs.

Depending on who you ask, this pilot is either a smart way to reduce duplicate discounts and
improve transparency, or a slow-motion attempt to shrink the 340B safety net while hospitals
and community health centers juggle new cash-flow headaches. Either way, it’s coming fast:
the rebate model is scheduled to launch on January 1, 2026.

In this in-depth guide, we’ll break down what the 340B Rebate Model Pilot Program is, how it
works, why it’s controversial, and what covered entities should be doing right now to get
readywithout needing a law degree, an actuary, and three cups of coffee at the same time.

Quick Refresher: What Is the 340B Drug Pricing Program?

The 340B Drug Pricing Program, created in 1992, requires drug manufacturers
that participate in Medicaid to sell covered outpatient drugs to eligible “covered entities”
(like safety-net hospitals, community health centers, and certain specialty clinics) at or
below a statutory ceiling price.

That ceiling price is generally calculated as the average manufacturer price (AMP) minus a
Medicaid unit rebate amount. In practice, this means 340B entities buy qualifying drugs at a
steep discount, then use the savings to support charity care, expand services, and improve
access for uninsured and underinsured patients.

Historically, 340B has been a point-of-sale discount program: covered entities
purchase drugs through wholesalers or directly from manufacturers at the discounted 340B
price. No complicated rebate chases. No waiting. Just lower acquisition cost at the front
end. The rebate model pilot flips that sequence around.

What Is the 340B Rebate Model Pilot Program?

The 340B Rebate Model Pilot Program is a HRSA initiative that allows
participating drug manufacturers to provide 340B pricing via post-purchase rebates
instead of upfront discountsbut only for a narrow group of drugs and under a tightly
structured pilot framework.

The pilot is:

• Voluntary for drug manufacturers that meet the criteria.
• Limited in scope to drugs subject to a Medicare Drug Price Negotiation
  Program (MDPNP) maximum fair price (MFP) for 2026.
• Nationwide in impact, because it applies to all 340B covered entities
  that purchase the selected drugs.

HRSA and HHS describe the model as a way to reduce duplicate discounts
(when a manufacturer unintentionally gives both a 340B discount and a Medicaid rebate on the
same unit of drug) and to improve oversight and adherence to the 340B statute, particularly
in a world where Medicare price negotiations under the Inflation Reduction Act (IRA) add a
new layer of complexity.

Key Dates and Timeline

• August 1, 2025: HRSA publishes a Federal Register notice outlining the
  application process for the pilot.
• September 15, 2025: Deadline for manufacturers with MDPNP agreements for
  2026 to submit participation plans.
• October 2025: HRSA approves plans for an initial set of
  manufacturers and drugs.
• January 1, 2026: Planned effective date for the pilot; rebates start
  replacing upfront discounts for the selected drugs.

Which Drugs Are Included?

The pilot focuses on a small group of high-spend drugs that are also part of the Medicare
negotiation list for 2026. Analysis from consulting and law firms as well as HRSA-related
materials identify the following as being included in the initial launch:​

• Eliquis
• Enbrel
• Entresto (initially eligible but not currently participating in the rebate model in some
  summaries)
• Farxiga
• Fiasp / NovoLog
• Imbruvica
• Januvia
• Jardiance
• Stelara
• Xarelto

Not every manufacturer of these drugs chose to participate, and some analyses note that
Entresto is excluded from the final list of rebate-model drugs despite being on the Medicare
negotiation list.

How the 340B Rebate Model Actually Works

In the current discount model, a covered entity buys a drug at the 340B price, uses it for an
eligible patient, and books the savings immediately. In the rebate model,
that flow looks more like a “buy now, get reimbursed later” adventure.

Step-by-Step: From Purchase to Rebate

1. Covered entities purchase at WAC: Instead of purchasing at the 340B price,
   the covered entity buys the selected drug at wholesale acquisition cost (WAC) from
   its usual wholesaler.
2. Claims-level data submission: The entity submits detailed claims data to a
   third-party vendor (such as Beacon Channel Management), including identifiers that show the
   drug was dispensed to a 340B-eligible patient and whether Medicaid is involved.
3. Deduplication and validation: Manufacturers or their vendors use that data
   to confirm that the unit isn’t also getting a Medicaid rebate or IRA maximum fair price
   discount, reducing the risk of duplicate discounts.
4. Rebate payment: Once validated, the manufacturer issues a rebate to the
   covered entity for the difference between WAC and the 340B ceiling price (or an equivalent
   arrangement), effectively delivering the 340B benefit after the fact.

In theory, the total savings over time should look similar to a traditional 340B
discount for those drugs. In practice, timing is everythingand timing is exactly what has
safety-net providers nervous.

Data and Compliance Requirements

The rebate model leans heavily on claims-level data. HRSA’s materials and
related legal and consulting analyses indicate that manufacturers may require:​

• National Drug Code (NDC)
• Quantity, date of service, and fill information
• Prescriber and site-of-care information
• Indicators of Medicaid coverage or coordination
• In some cases, limited medical claims data fields (diagnosis or procedure indicators) tied
  to eligibility and deduplication

HRSA has stated that rebates should not be denied solely based on diversion
or Medicaid duplicate-discount concerns; those issues should instead be addressed through
standard compliance and audit channels. Still, the amount of
data sharing in the rebate model has raised understandable questions about privacy, workload,
and the risk of retroactive disputes.

Why HRSA Is Doing This: Policy Goals

Officially, HRSA frames the 340B Rebate Model Pilot Program as a way to:

• Reduce duplicate discounts between 340B, Medicaid rebates, and now IRA
  maximum fair prices.
• Improve transparency and oversight by tying discounts to detailed claims
  data rather than relying purely on program integrity audits after the fact.
• Test a limited, data-driven approach to see whether a rebate model can
  address long-standing disputes between manufacturers and providers.

For years, drug manufacturers have argued that they lack visibility into where discounted 340B
drugs actually land and whether those units are also being claimed for Medicaid rebates.
A rebate model, where payment is contingent on verified claims, solves that visibility
problem from their perspective.

Why the Rebate Model Is So Controversial

If the goal is transparency and deduplication, why are hospital and provider groups
filing lawsuits and warning that the pilot could “destroy” the 340B program as they know
it? Let’s unpack the main concerns.

Cash-Flow and Working Capital Pressures

Under the rebate model, covered entities must first buy drugs at full WAC and
only later receive rebates. For high-cost specialty drugs like Stelara, Imbruvica, or
Xarelto, that’s not a rounding-error problemthat’s a “do we have enough cash this month?”
problem.

Commentaries from provider advocates and 340B service vendors emphasize that:

• Safety-net providers already operate on thin margins.
• Delays or disputes in rebate payments could translate into real cuts in services.
• Some health systems are exploring short-term loan arrangements just to cover the gap
  between WAC purchases and rebate receipt.

In short, the pilot may not reduce savings on paperbut it changes when those
savings show up, and timing can be the difference between expanding a behavioral health
program and freezing hiring.

Legal and Policy Challenges

Several hospital groups, including national trade associations, have already filed lawsuits
seeking to block the pilot. They argue that HRSA has overstepped its statutory authority by
effectively rewriting the mechanics of 340B without explicit congressional authorization.

Opponents also worry about precedent: if a rebate model can be imposed (even in a “voluntary”
pilot) for high-cost drugs today, what stops it from becoming the norm across a much wider
slice of the formulary tomorrow?

Impact on Patients and Community Programs

Provider groups repeatedly stress that 340B is not just a back-office pricing mechanismit’s
a financial engine for charity care and community benefits. Some hospital systems report
reinvesting billions annually from 340B savings into free clinics, transportation programs,
outreach, and uncompensated care.

If cash-flow disruption or rebate uncertainty forces entities to pull back, the people who
feel the impact first are patients: fewer services, longer waits, or tighter eligibility for
financial assistance. That’s why many safety-net providers see the rebate model less as a
technical tweak and more as a fundamental risk to how they keep the lights on.

What Covered Entities Should Be Doing Right Now

Even with litigation underway and policy debates raging, the clock toward January 1, 2026 is
still ticking. Advisory firms, 340B consultants, and compliance experts are all converging on
a common theme: get operationally ready, fast.

1. Map Your Exposure

Start by identifying how much you currently spend on, and save from, the drugs included in
the pilot:

• Look at historical utilization by site (inpatient, outpatient, contract pharmacy).
• Break out payer mix, especially Medicaid and Medicare.
• Estimate what WAC purchasing would look like compared with current 340B acquisition
  cost.

This gives you a realistic baseline for how much cash you’ll need to float while waiting for
rebates.

2. Stress-Test Your Cash Flow

Work with your finance team (and, if needed, consultants or actuaries) to model scenarios:

• How long does it take to receive rebates in best-, moderate-, and worst-case scenarios?
• What happens if a portion of claims is denied or delayed due to data mismatches?
• What temporary financing or reserves are available, and at what cost?

Some organizations are exploring short-term credit lines or internal “bridge” funds targeted
specifically to 340B cash-flow gaps.

3. Get Your Data Infrastructure in Shape

The rebate model lives and dies on data quality. Covered entities should:

• Confirm which third-party vendor(s) will handle rebate files and how data will flow.
• Align internal identifiers (NDCs, locations, prescribers, and patient flags) with vendor
  requirements.
• Conduct test file submissions, if allowed, to catch formatting and mapping issues early.
• Establish internal controls and audit trails to document eligibility decisions.

Vendors and 340B-focused technology companies are already marketing automation tools to
streamline file creation, submission, and reconciliationworth exploring if your team is
already stretched thin.

4. Revisit Policies, Procedures, and Training

Because the pilot adds new data and financial flows, it’s a good time to:

• Update 340B policies to reflect rebate workflows and responsibilities.
• Clarify who owns whatpharmacy, revenue cycle, finance, IT, and compliance all have
  roles.
• Educate clinicians and frontline staff on how drug selection decisions may intersect with
  340B and rebate dynamics.

You don’t want your first conversation about the rebate model to happen when someone notices
that the pharmacy account just blew through its WAC budget in week two of January.

What to Watch in 2026 and Beyond

As the pilot rolls out, several metrics and developments will determine whether it’s viewed
as a successful modernization or a cautionary tale:

• Rebate timing: Are payments predictable and timely, or are entities
  waiting months?
• Denial rates: How often are claims rejected due to data issues or
  eligibility disputes?
• Operational burden: Do the administrative costs of the rebate model chew
  up a meaningful portion of the savings?
• Impact on patient services: Are providers reporting any cutbacks blamed
  on cash-flow disruption?
• Regulatory and legal outcomes: Do lawsuits or future guidance narrow,
  expand, or reshape the pilot?

HRSA has framed this as an experiment. Like all experiments, the real story will be told in
the dataand in the lived experience of covered entities trying to serve patients while the
rules of their primary drug-discount program keep evolving.

Experiences and Practical Lessons Around the 340B Rebate Model

Although the 340B Rebate Model Pilot Program doesn’t officially go live until January 1,
2026, many covered entities and vendors have already spent months preparingand those
preparations offer valuable “early experience” lessons.

1. The Reality of Preemptive Cash-Flow Planning

One recurring theme from health systems that have dug into the numbers is that
cash-flow modeling is more complicated than expected. Finance teams are
discovering that it isn’t just about the size of the rebate; it’s about the timing of when
that rebate hits the books.

For example, a medium-sized safety-net hospital might realize that its annual 340B savings on
pilot drugs is comfortably in the seven-figure range. On paper, that looks reassuring. But
once they simulate buying those same drugs at WAC for 60–90 days before the first rebates are
paid, they find that pharmacy working capital needs to increase sharply. That forces
leadership to rethink capital projects, delay equipment purchases, or renegotiate credit
lines just to give the pharmacy budget enough breathing room.

Some specialized 340B administrators and vendors have responded by designing short-term loan
or advance programs that effectively “front” some portion of the expected rebate. These
arrangements can be helpful, but they also introduce new questions: what happens if a portion
of the rebate doesn’t materialize, or if timing slips? That uncertainty is shaping how risk
managers, CFOs, and boards talk about the pilot internally.

2. Data Clean-Up Is No Longer Optional

Early technical testing with vendors has highlighted a second lesson:
messy data equals delayed money. Covered entities that treated 340B
crosswalks and claim flags as “nice to have but eventually we’ll fix it” are finding out
that, under the rebate model, bad mapping can directly delay or reduce rebate payments.

Health systems that invested early in:

• Standardizing NDC-level purchasing and dispensing data,
• Cleaning up payer and Medicaid carving indicators, and
• Aligning EMR, pharmacy, and billing systems around a single source of truth

report smoother test cycles with vendors and more confidence that rebate files will pass
validation checks. Others are discovering late in the game that prescriber IDs don’t match,
location codes are inconsistent, or diagnosis data lives in a separate system that isn’t
reflected in the pharmacy file. Those gaps can slow down implementation dramatically.

3. Communication Inside the Organization Matters More Than Expected

Another on-the-ground insight: the rebate model isn’t just a pharmacy or compliance story. It
touches finance, revenue cycle, IT, legal, and clinical leadership. Health
systems that have treated it as a cross-functional change management projectcomplete with
steering committees, regular updates, and documented workflowstend to feel more prepared.

In contrast, organizations where 340B discussions happen in a silo are now scrambling to
answer basic questions:

• Who approves WAC-level purchasing volume for pilot drugs?
• Who owns the relationship with the third-party rebate vendor?
• How are disputes with manufacturers escalated and resolved?
• How do clinicians get feedback if their prescribing patterns impact rebate exposure?

Early experiences suggest that answering these questions up frontrather than during the
first quarter of the pilotcan prevent a lot of finger-pointing later.

4. Balancing Cautious Skepticism with Pragmatic Readiness

Perhaps the most important experiential lesson is psychological: it’s possible to
oppose the policy changes while still preparing for them.
Many provider advocates are loud critics of the rebate model, warning that it could erode the
340B safety net. At the same time, administrators inside those very
organizations are quietly building data pipelines, updating policies, and teaching teams how
the new workflow will function.

That dual mindset“we’re fighting this, but we’re also ready if it goes live”is becoming a
defining feature of how experienced 340B leaders navigate the current environment. It’s not
emotionally satisfying, but it’s realistic in a program where litigation, guidance, and
operations have always moved on parallel tracks.

Conclusion: A Pilot with High Stakes for the 340B Safety Net

HRSA’s 340B Rebate Model Pilot Program is more than a technical billing experimentit’s a
high-stakes test of how far the government and manufacturers can reshape 340B mechanics while
still preserving the core mission of supporting safety-net providers and their patients.

On one hand, the pilot promises more precise data, fewer duplicate discounts, and better
alignment with new Medicare price negotiations under the IRA. On the other hand, it risks
destabilizing the cash flow that many hospitals and clinics rely on to fund critical
community services.

For covered entities, the most pragmatic approach is to engage on every front: participate in
policy discussions, follow litigation developments, andat the same timeprepare operational
systems, finances, and teams as if the pilot will proceed as scheduled. The rules of 340B may
be changing, but the mission isn’t. Patients still need access, and providers still need a
viable way to pay for it.